Use of prostate-specific antigen (PSA) to measure semen exposure resulting from male condom failures: implications for contraceptive efficacy and the prevention of sexually transmitted disease
- 1 February 2003
- journal article
- Published by Elsevier in Contraception
- Vol. 67 (2) , 139-150
- https://doi.org/10.1016/s0010-7824(02)00478-x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptivesContraception, 2001
- Comparative evaluation of three TactylonTM condoms and a latex condom during vaginal intercourse: breakage and slippageContraception, 2000
- Evaluation of prostate-specific antigen as a quantifiable indicator of condom failure in clinical trialsContraception, 1999
- Evaluation of the Efficacy of a Polyurethane Condom: Results from a Randomized, Controlled Clinical TrialFamily Planning Perspectives, 1999
- Prostate-specific antigen in vaginal fluid as a biologic marker of condom failureContraception, 1999
- Objective Markers of Condom FailureSexually Transmitted Diseases, 1998
- Timing of Sexual Intercourse in Relation to Ovulation — Effects on the Probability of Conception, Survival of the Pregnancy, and Sex of the BabyNew England Journal of Medicine, 1995
- Standardized protocols for condom breakage and slippage trials: a proposal.American Journal of Public Health, 1994
- Conception Rate According to Semen Characteristics in a Series of 15 364 Insemination Cycles: Results of a Multivariate AnalysisAndrologia, 1985
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977